

# **New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in Malaysia**

Singapore, 29 March 2022: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now available in Malaysia. The drug, NERLYNX® (neratinib) is an oral medication taken for 12 months by women who have been diagnosed with early stage HER2-positive (HER2+) breast cancer and who have received prior trastuzumab-based therapy.